Skip to main content
NewslettersWatchlist

Neurocrine Bioscienc(NBIX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Neurocrine Biosciences Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH)

PR Newswire - Tue Sep 12, 2023

CAHtalyst™ Met Primary Endpoint Demonstrating a Statistically Significant Decrease from Baseline Daily Glucocorticoid Dose with Androgen Control

Key Secondary Endpoint Achieved Statistically Significant Decrease in Androstenedione at Week 4 versus Placebo

Read more at prnewswire.com

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe

inside the market
Dividend investing has lost its mojo. Here’s why – and how to adapt
Ian McGugan
inside the market
The Globe Investing Club 2024: Let the competition begin!
opinion
Here’s the real reason your Canadian stocks can’t keep up
Tim Shufelt
market news
Dow ends above 40,000 milestone, TSX also at fresh record high
Traders work on the floor of the New York Stock Exchange (NYSE) on May 16.
number cruncher
U.S technology stocks with earnings and price momentum
For Number Cruncher column in Globe Investor/ROB only.
report on business
Lightspeed Commerce stock soars on better-than-expected profit forecast
Lightspeed Commerce Inc. CEO Dax Dasilva poses in the company's offices in Montreal, Wednesday, May 8, 2024. THE CANADIAN PRESS/Christinne Muschi
globe investor
GameStop, AMC dive further as meme stocks rally tapers off
A screen displays the trading information for GameStop and AMC Theatres on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., May 15.
market news
The close: Dow briefly hits 40,000 milestone, TSX rises on upbeat earnings
The Art Deco facade of the original Toronto Stock Exchange building is seen on Bay Street in Toronto in January of 2019.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).